A hard pill to swallow: a qualitative study of women's experiences of adjuvant endocrine therapy for breast cancer
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Objective: To explore women's experiences of taking adjuvant endocrine therapy as a treatment for breast cancer and how their beliefs about the purpose of the medication, side effects experienced and interactions with health professionals might influence adherence. Design: Qualitative study using semistructured, one-to-one interviews. Setting: 2 hospitals from a single health board in Scotland. Participants: 30 women who had been prescribed tamoxifen or aromatase inhibitors (anastrozole or letrozole) and had been taking this medication for 1–5 years. Results: Women clearly wished to take their adjuvant endocrine therapy medication as prescribed, believing that it offered them protection against breast cancer recurrence. However, some women missed tablets and did not recognise that this could reduce the efficacy of the treatment. Women did not perceive that healthcare professionals were routinely or systematically monitoring their adherence. Side effects were common and impacted greatly on the women’s quality of life but did not always cause women to stop taking their medication, or to seek advice about reducing the side effects they experienced. Few were offered the opportunity to discuss the impact of side effects or the potential options available. Conclusions: Although most women in this study took adjuvant endocrine therapy as prescribed, many endured a range of side effects, often without seeking help. Advice, support and monitoring for adherence are not routinely offered in conventional follow-up settings. Women deserve more opportunity to discuss the pros, cons and impact of long-term adjuvant endocrine therapy. New service models are needed to support adherence, enhance quality of life and ultimately improve survival. These should ideally be community based, in order to promote self-management in the longer term.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Qualitative data analysis for applied policy research
Ritchie, J., & Spencer, L. (2010) · Analyzing qualitative data · doi:10.4324/9780203413081_chapter_9 · Cited by 4,800
Gibbs, G. (2007) · doi:10.4135/9781849208574 · Cited by 4,299
Horne, R., & Weinman, J. (1999) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(99)00057-4 · Cited by 2,201 · cited 1×
“In our analysis we drew on, but were not limited by, the work of Horne and Weinman 36 who use illness representation theory to show that while illness beliefs play a role in adherence, patients ’ beliefs about the necessity of their treatment also have a direct role in medication adherence.”
Hershman, D. L., Shao, T., Kushi, L. H., Buono, D., Tsai, W. Y., Fehrenbacher, L., Kwan, M., Gomez, S. L., & Neugut, A. I. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1132-4 · Cited by 870
Murphy, C. C., Bartholomew, L. K., Carpentier, M. Y., Bluethmann, S. M., & Vernon, S. W. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2114-5 · Cited by 708 · cited 1×
“adherence in terms of number of pills taken and the impact on recurrence and mortality.(27) These aggregated numerical data fail to capture the diverse patterns of adherence or the complex factors which may lead to”
Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
Partridge, A. H., Wang, P. S., Winer, E. P., & Avorn, J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.07.071 · Cited by 676
Cuzick, J., Sestak, I., Forbes, J. F., Dowsett, M., Knox, J., Cawthorn, S., Saunders, C., Roche, N., Mansel, R. E., von Minckwitz, G., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62292-8 · Cited by 590
McCowan, C., Shearer, J., Donnan, P. T., Dewar, J. A., Crilly, M., Thompson, A. M., & Fahey, T. P. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604758 · Cited by 343 · cited 1×
“001), reduced quality-adjusted life years (QALYs) and increased medical costs (£5970, 95% CI £4644 to £7372).(14) 15 Adjuvant endocrine therapy with either tamoxifen or an AI has a significant side effect profile.”
Self-citationCohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality
Makubate, B., Donnan, P. T., Dewar, J. A., Thompson, A. M., & McCowan, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.116 · Cited by 298
Self-citationPatient Centered Experiences in Breast Cancer: Predicting Long-Term Adherence to Tamoxifen Use
Kahn, K. L., Schneider, E. C., Malin, J. L., Adams, J. L., & Epstein, A. M. (2007) · Medical Care · doi:10.1097/01.mlr.0000257193.10760.7f · Cited by 245
Cited by
Understanding tamoxifen adherence in women with breast cancer: A qualitative study
Moon, Z., Moss‐Morris, R., Hunter, M. S., & Hughes, L. D. (2017) · British Journal of Health Psychology · doi:10.1111/bjhp.12266 · Cited by 112
Brett, J., Fenlon, D., Boulton, M., Hulbert-Williams, N. J., Walter, F. M., Donnelly, P., Lavery, B., Morgan, A., Morris, C., & Watson, E. (2018) · European Journal of Cancer Care · doi:10.1111/ecc.12601 · Cited by 98
Finitsis, D. J., Vose, B. A., Mahalak, J. G., & Salner, A. L. (2019) · Psycho-Oncology · doi:10.1002/pon.4959 · Cited by 68
Oncology providers’ perspectives on endocrine therapy prescribing and management
Wheeler, S., Roberts, M., Bloom, D., Reeder-Hayes, K., Espada, M., Peppercorn, J., Golin, C., & Earp, J. A. (2016) · Patient Preference and Adherence · doi:10.2147/ppa.s95594 · Cited by 31
Hall, L. H., Clark, J., Smith, S. G., Graham, C. D., & for the ACTION investigators (2022) · Journal of Psychosocial Oncology · doi:10.1080/07347332.2021.1955318 · Cited by 10
Metadata
- Authors
- Harrow, A., Dryden, R., McCowan, C., Radley, A., Parsons, M., Thompson, A. M., & Wells, M.
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2014-06
- Volume
- 4
- Issue
- 6
- Pages
- e005285
- ISSN
- 2044-6055 (ISSN-L)
- OpenAlex
- W2106251515
- Cited by
- 83
- References
- 16
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.